Today Tiba was awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the U.S. National Institutes of Health. In response to an earlier Notice of Special Interest, this six-month grant is to develop an RNA-based multi-antigen vaccine for SARS-CoV-2.
Today Tiba was awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the U.S. National Institutes of Health. In response to an earlier Notice of Special Interest, this six-month grant is to develop an RNA-based multi-antigen vaccine for SARS-CoV-2.
Tiba scientists are working with our academic collaborators at the University of Pittsburg and Carnegie Mellon University to design a new approach to mRNA vaccine delivery. The combined stability of our nanoparticles and the dosing efficiency of a micro-needle patch offer new opportunities for healthcare professionals in resource-limited settings.
Tiba’s co-founder and mRNA visionary, Christian Mandl, spoke at the Global Vaccine and Immunization Research Forum 2021, the central forum for research related to the Immunization Agenda 2030 (IA2030). GVIRF is the only global meeting that brings together the entire Vaccine and Immunization Research community, from basic immunology to implementation research, and from low to high income countries.
Leveraging the University’s Center for Vaccine Research, an NIH Regional Biocontainment Laboratory, Tiba scientists are collaborating with researchers at the University of Pittsburg to advance a novel COVID-19 mRNA vaccine.
© 2024 Tiba Biotech LLC. All rights reserved
